Adolescent adiposity was associated with adverse cardiovascular risk markers at 21-23 years, including a ~+2 mm Hg rise in systolic blood pressure between 11-13 and 21-23 years.
Cohort (n=6,643)
Yes
Does adolescent adiposity influence cardiovascular disease risk markers in early adulthood?
Adolescent adiposity is significantly associated with adverse cardiometabolic risk markers in early adulthood, highlighting the importance of early intervention.
OBJECTIVE: To examine influences of adiposity from early adolescence to early 20s on cardiovascular disease (CVD) risk in the multiethnic Determinants of young Adult Social well-being and Health (DASH) longitudinal study. METHODS: In 2002-2003, 6643 11-13-year-olds from 51 London schools participated at baseline, and 4785 were seen again at 14-16 years. Recently, 665 (97% of invited) participated in pilot follow-up at 21-23 years, with biological and psychosocial measures and blood biomarkers (only at 21-23 years). Regression models examined interplay between ethnicity, adiposity and CVD. RESULTS: At 21-23 years, ∼30-40% were overweight. About half of the sample had completed a degree with little ethnic variation despite more socioeconomic disadvantage in adolescence among ethnic minorities. Regardless of ethnicity, overweight increased more steeply between 14-16 years and 21-23 years than between 11-13 years and 14-16 years. More overweight among Black Caribbean and Black African females, lower systolic blood pressure (sBP) among Indian females and Pakistani/Bangladeshi males compared with White UK peers, persisted from 11-13 years. At 21-23 years, glycated haemoglobin (HbA1c) was higher among Black Caribbean females, total cholesterol higher and high-density lipoprotein (HDL) cholesterol lower among Pakistani/Bangladeshis. Overweight was associated with a ∼+2 mm Hg rise in sBP between 11-13 years and 21-23 years. Adiposity measures at 11-13 years were related to allostatic load (a cluster of several risk markers), HbA1c and HDL cholesterol at 21-23 years. Ethnic patterns in CVD biomarkers remained after adjustments. CONCLUSIONS: Adolescent adiposity posed significant risks at 21-23 years, a period in the lifespan generally ignored in cardiovascular studies, when ethnic/gender variations in CVD are already apparent.
Harding et al. (Thu,) conducted a cohort in Cardiovascular disease risk (n=6,643). Adiposity vs. Lower adiposity was evaluated on Cardiovascular disease risk markers (sBP, HbA1c, HDL cholesterol, allostatic load). Adolescent adiposity was associated with adverse cardiovascular risk markers at 21-23 years, including a ~+2 mm Hg rise in systolic blood pressure between 11-13 and 21-23 years.